Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 26Leukemia, Lymphocytic, Chronic, B-Cell 6Leukemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid 2Renal Insufficiency, Chronic 1Recurrence 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Older Patients 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Prolymphocytic, T-Cell 1Hematologic Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

venetoclax 1ruxolitinib 1Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Leukemia, Prolymphocytic, T-Cell × venetoclax × Clear all
NCT07311746 2025-12-31

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡